NCT01753453View on ClinicalTrials.gov

An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Multiple Myeloma
Interventions
DRUG

Plerixafor

240mcg/kg, solution, subcutaneous injection

DRUG

Granulocyte-colony stimulating factor (G-CSF)

10 mcg/kg, solution, subcutaneous injection

Trial Locations (5)

13419

Investigational Site Number 233001, Tallinn

14186

Investigational Site Number 752001, Stockholm

B-8000

Investigational Site Number 056002, Bruges

LT-08661

Investigational Site Number 440001, Vilnius

901 85

Investigational Site Number 752002, Umeå

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

Sanofi

INDUSTRY